Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “EGFR-TKI”

279 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 279 results

Testing effectiveness (Phase 2)Study completedNCT03544814
What this trial is testing

EGFR-TKI Combined With Concurrent or Sequential Chemotherapy for Patients of Gradual Progression

Who this might be right for
Lung AdenocarcinomaEGFR Activating Mutation
Shanghai Chest Hospital 99
Testing effectiveness (Phase 2)Study completedNCT00660816
What this trial is testing

Pemetrexed or Docetaxel With or Without Erlotinib in Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Who this might be right for
Lung Cancer
Case Comprehensive Cancer Center 46
Post-approval studies (Phase 4)Study completedNCT01465243
What this trial is testing

Dose Escalation Of Icotinib In Previously Treated Patients With Routine Dose

Who this might be right for
Non-small Cell Lung Cancer
Betta Pharmaceuticals Co., Ltd. 32
Large-scale testing (Phase 3)Ended earlyNCT04816214
What this trial is testing

Study Evaluating Efficacy and Safety of Capmatinib in Combination With Osimertinib in Adult Subjects With Non-small Cell Lung Cancers as Second Line Therapy

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Novartis Pharmaceuticals 6
Testing effectiveness (Phase 2)Looking for participantsNCT05284539
What this trial is testing

Efficacy of Platinum-based Chemotherapy Plus Immune Checkpoint Inhibitors for EGFR/ALK/ROS1 Mutant Lung Cancer

Who this might be right for
Non Small Cell Lung Cancer
Hunan Province Tumor Hospital 760
Testing effectiveness (Phase 2)Study completedNCT03623750
What this trial is testing

E GFR TKI and EGF-P TI C Ombination in EGFR mutA nt NSCL C

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Instituto Oncológico Dr Rosell 23
Testing effectiveness (Phase 2)Study completedNCT00922584
What this trial is testing

Sorafenib Treatment in Non-Small Cell Lung Cancer After Failure of Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor

Who this might be right for
Non-Small Cell Lung Cancer
Chinese Society of Lung Cancer 65
Testing effectiveness (Phase 2)Looking for participantsNCT06071013
What this trial is testing

Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients

Who this might be right for
Non-small Cell Lung CancerEGFR Gene MutationEGFR-TKI Resistant Mutation
China Medical University Hospital 20
Testing effectiveness (Phase 2)UnknownNCT04470076
What this trial is testing

Neoadjuvant Afatinib Combination With Chemotherapy for Stage Ⅱa-Ⅲb NSCLC With EGFR Activating Mutation

Who this might be right for
Non Small Cell Lung CancerSurgeryEGFR Activating Mutation+2 more
Fifth Affiliated Hospital, Sun Yat-Sen University 30
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06018688
What this trial is testing

Osimertinib Combined With Aspirin Neoadjuvant Therapy for Resectable EGFR Mutated NSCLC Patients.

Who this might be right for
Non Small Cell Lung CancerEGFR Gene Mutation
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University 44
Not applicableEnded earlyNCT02405247
What this trial is testing

TAURAS - T790 AURA ScreenFailure SOC Registry Study

Who this might be right for
Non Small Cell Lung Cancer
AstraZeneca 400
Large-scale testing (Phase 3)UnknownNCT02859077
What this trial is testing

EGFR-TKI With Chemotherapy in NSCLC Patients With Both EGFR Mutation and BIM Deletion Polymorphism

Who this might be right for
Non-Small-Cell Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China 100
Not applicableUnknownNCT06095934
What this trial is testing

Efficacy and Safety of Neoantigen Peptide Vaccine in the Treatment of Advanced NSCLC Progressed After EGFR-TKI Treatment

Who this might be right for
NSCLCEGFR Gene Mutation
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School 20
Not applicableStudy completedNCT02575560
What this trial is testing

Weekly Use First-generation EGFR-TKI in the Treatment of EGFR-TKI Acquired Resistance Non-small Cell Lung Cancer (NSCLC)

Who this might be right for
EGFR-TKI Resistant Mutation
Qingdao Central Hospital 30
Large-scale testing (Phase 3)UnknownNCT03924050
What this trial is testing

Toripalimab Plus Pemetrexed+Platinus in Advanced Non-small-cell Lungcancer Patients Previsouly Treated EGFR-TKI

Who this might be right for
Non-small Cell Lung Cancer
Shanghai Junshi Bioscience Co., Ltd. 440
Early research (Phase 1)Active Not RecruitingNCT05364073
What this trial is testing

Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations

Who this might be right for
Non-Small Cell Lung Cancer (NSCLC)Metastatic Non-Small Cell Lung CancerAdvanced Non-Small Cell Lung Cancer+3 more
ArriVent BioPharma, Inc. 160
Not applicableLooking for participantsNCT06304441
What this trial is testing

Intra-pemetrexed Plus Third-generation Small Molecule TKI Drugs (e.g. 'Osimertinib') Versus Third-generation Small Molecule TKI Drugs Alone for Leptomeningeal Metastasis From Epidermal Growth Factor Receptor Mutation-Positive Non-Small-cell Lung Cancer

Who this might be right for
Leptomeningeal Metastasis
Guangzhou Medical University 100
Testing effectiveness (Phase 2)UnknownNCT03461185
What this trial is testing

Anti-angiogenesis Combine With EGFR-TKI in Advanced Non-squamous Non Small Cell Lung Cancer

Who this might be right for
Non Small Cell Lung Cancer
Xinqiao Hospital of Chongqing 100
Testing effectiveness (Phase 2)Study completedNCT01588145
What this trial is testing

Phase I/II Trial to Evaluate Safety, Tolerability and Pharmacokinetic Profile of HM61713 in NSCLC Patients

Who this might be right for
Non Small Cell Lung Cancer
Hanmi Pharmaceutical Company Limited 273
Testing effectiveness (Phase 2)Looking for participantsNCT06924398
What this trial is testing

Postoperative EGFR-TKI Therapy forContralateral Pulmonary Nodules in Patients With EGFR-Mutant NSCLC（ARMOR2501）

Who this might be right for
Lung Cancer (NSCLC)
Sun Yat-sen University 32
Load More Results